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Stent thrombosis (ST) is a rare but potentially life-threatening event that can occur
following percutaneous coronary intervention (PCI) with stent implantation. Several
factors related to the procedure or patient features can favor thrombus formation and
development of ST. Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 inhibitors is
the cornerstone of strategy for reducing incidence of ST. Two main causes of DAPT failure
have been identiﬁed: the inappropriately premature antiplatelet therapy discontinuation
and hyporesponsiveness to antiplatelet drugs. There is growing evidence that a residual
high on treatment platelet reactivity (HPR) is associated with increased risk of thrombotic
complications after PCI, including ST. In recent years numerous platelet function tests
were developed and some of these have been extensively used in clinical studies to
evaluate residual platelet reactivity, after antiplatelet drugs administration. The identiﬁca-
tion of patients with HPR is fundamental for optimization of antiplatelet treatment.
Nevertheless ﬁrst studies suggested that achieving a more intense platelet inhibition,
switching from standard to an intensiﬁed treatment regimen on the basis of platelet
reactivity, has failed to show any beneﬁt in terms of clinical events. Certainly individua-
lized pharmacological treatment of patients undergoing PCI remains one of the most
important objectives in order to prevent serious PCI complications, such us ST.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Percutaneous coronary intervention (PCI) with stent implan-
tation is currently the treatment of choice for coronary
revascularization in patients affected by coronary artery
disease (CAD). Although the introduction of dual antiplatelet
therapy (DAPT) with aspirin and P2Y12 inhibitors has resulted
in a dramatic decrease in the incidence of recurrent ischemic
complications after PCI [1–3], cardiovascular events following
stent implantation still occur in a clinically signiﬁcant pro-
portion of patients [4,5]. Stent thrombosis (ST) is a potentially
life-threatening event, most frequently associated with ST
elevation myocardial infarction (STEMI) or sudden cardiac
death, resulting from abrupt vessel closure. Mortality rates
associated with ST vary from 20% to 45% [6–9].2. Stent thrombosis and platelet inhibition
The Academic Research Consortium (ARC) has elaborated
speciﬁc criteria for ST diagnosis, with the aim to propose a
deﬁnition that could be uniformly applied in clinical trials
and daily practice. According to the degree of certainty, ST is
deﬁned as “deﬁnite” in the presence of angiographic or
pathologic conﬁrmation; “probable” in case of unexplained
death occurring within 30 days after the procedure, or
myocardial infarction (MI) at any time in the territory of
implanted stent; “possible” when unexplained death occurs
beyond 30 days from procedure. According to the time of
presentation, ST is deﬁned as “acute” (within 24 h from stent
implantation), “early” (occurring in the ﬁrst 30 days after
stent implantation), “late” (between 31 days and 12 months
from the index procedure) and “very late” (after 12 months
from angioplasty) [10]. Several factors can favor thrombus
formation and development of ST [7–9,11–18]. Acute ST is
generally associated to “procedure related” factors, such as
stent underexpansion or malapposition, “edge” dissection,
stent fracture, reduced TIMI (thrombolysis in myocardial
infarction) ﬂow grade at the end of the procedure [7,9,13].
Early and late ST are usually related to lesion characteristics:
long lesion length, small vessel diameter, treatment of
saphenous vein graft, chronic total occlusion or bifurcation
lesions are predictors of increased risk of ST [7–9,11,12].
Similarly, various clinical characteristics are strongly asso-
ciated with the risk of ST: diabetes mellitus, acute coronary
syndrome, neoplasms, advanced age, hypersentivity to poly-
mer or drug, discontinuation of DAPT or hyposensitivity to
antiplatelet drug [7–9,11,12,14–16]. Finally risk factors for very
late stent thrombosis are still not well characterized, but
instrumental and pathological evidences have underlined the
fundamental role of incomplete stent healing and local
inﬂammation in the development of ST also after several
years from PCI [17,18].
Nowadays the maintenance of adequate platelet inhibi-
tion is the cornerstone of ST prevention and DAPT is the
mainstay strategy for reducing incidence of ST. Two main
causes of DAPT failure have been identiﬁed: the inappropri-
ately premature antiplatelet therapy discontinuation and
hyporesponsiveness to antiplatelet drugs. Many observationalstudies have shown a clear relation between premature DAPT
discontinuation and poor clinical outcomes, especially in drug
eluting stent (DES) treated patients [8,19–21]. In the PREMIER
registry, among 500 MI patients treated with DES, mortality
rates at 1-year were signiﬁcantly higher in patients who
withdrew thienopydirine treatment than in those who con-
tinued appropriate therapy (7.5% vs. 0.7%, Po0.0001) [8]. In a
series of 3021 DES treated patients, the rate of ST at 18
months was 1.9% (58 patients) and the rate of ST within 6
months is 1.4% (42 patients). Data frommultivariable analysis
identiﬁed P2Y12 inhibitors discontinuation as a major inde-
pendent predictor of ST within 6 months (HR 13.74; 65% CI,
4.04–46.68; Po0.001) [21]. A retrospective analysis in 1293
patients treated with sirolimus eluting stent found no sig-
niﬁcant difference between treatment with DAPT withdrawn
within or beyond 6 months (1.3% vs. 2.6%, P¼0.197). However,
patients treated with DAPT for longer than 6 months pre-
sented a signiﬁcantly higher incidence of major bleeding (HR
3.623; 95% CI, 1.763–7.444; Po0.001), including intracranial
hemorrhage (HR 4.545; 95% CI; 1.083–19.068, P¼0.039) [22].
Concern about bleeding complications is also due to the
evidence of their important clinical impact on outcomes of
patients undergoing PCI [23,24]. A subsequent study on a
population of 2701 patients treated with DES has shown that
treatment with DAPT, for more than 12 months, was not
signiﬁcantly more effective than aspirin alone [25]. No differ-
ence in the incidence of ST was found in another study of
2013 patients randomized to receive DAPT for 6 vs. 24 months
[26]. Despite current guidelines recommending DAPT for 6–12
months after DES implantation and for 12 months after an
acute coronary syndrome regardless of the type of stent
implanted [27], data on optimal DAPT timing are not con-
clusive, and maybe deﬁnitive answers could come from
several ongoing randomized clinical trials [28,29].3. The role of platelet reactivity
Recently, the discussion about antiplatelet treatment has
focused on the problem of responsiveness to drug treatment.
Various investigations have shown that in patients with
decreased response to clopidogrel, residual high platelet
reactivity (HPR) is associated with increased risk of thrombo-
tic complications after PCI [30–38]. Numerous platelet func-
tion tests are nowadays available, some of which have been
extensively used in clinical studies to evaluate residual
platelet reactivity after antiplatelet drugs administration
[39]. Light transmittance aggregometry (LTA) is actually
considered the gold standard methods to assess platelet
function. It is based on the measure of light transmission
through platelet rich plasma after exposure to an agonist (i.e.
adenosine diphosphate) with platelet poor plasma as refer-
ence. This method requires special training and it is time
consuming, therefore may not be suitable for routine clinical
use [40,41]. Another method is the platelet vasodilator-
stimulated phosphoprotein (VASP) phosphorylation assess-
ment, which is based on the ﬂow cytometry evaluation of
P2Y12 receptor inhibition. Similarly to LTA, this assay is not
routinely used in clinical practice as it requires dedicated
training and time-consuming laboratory procedures [40,42].
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 1 5 1 – e 1 5 7 e153Currently, several tests are also available for a point of care
evaluation of platelet reactivity: the Verify-Now P2Y12 (Accu-
metrics Inc., San Diego, California), the Multiplate analyzer
(Dynabyte, Munich, Germany), the Platelet Function Assay-
100 (PFA-100 System; Dade Behring, Miami, Fla) and Platelet-
works (Helena Laboratories, Beaumont, Texas) assays. In
particular the Verify-Now P2Y12 assay is based on the
measure of ADP-induced platelet aggregation, with results
reported as P2Y12 reaction units (PRU). The lower the PRU
value, the greater the degree of P2Y12 receptor inhibition by
clopidogrel and vice versa [40,43]. The Multiplate analyzer is
based on impedance multiple electrode platelet aggregometry
(MEA) and the results are reported as aggregation units (AU).
Both assays do not require a particular training, are not time
consuming and require whole blood samples [40,44].
A large proportion of patients treated with clopidogrel
show an impaired response to this drug and high residual
platelet reactivity [42,44–50], which has been extensively
demonstrated to result in increased rates of ischemic com-
plications after PCI [28–36]. In the CREST study patients who
experienced ST had signiﬁcantly higher platelet reactivity in
clopidogrel, as assessed with LTA, VASP, and greater inci-
dence of HPR (deﬁned as475th percentile for 5 and 20 μmol/l
ADP induced aggregation in the group without ST and 475th
percentile of VASP values) [46]. Similarly, Hobson et al. found
signiﬁcantly higher platelet reactivity on clopidogrel in
patients with ST, using the Verify-Now P2Y12 (PRU 183751
vs. 108731, P¼0.02) [47]. In a Swedish Registry, mean PRU
levels during clopidogrel treatment was found to be higher in
patients with ST than in control (246.8775.98 vs. 200.0782.7,
P¼0.001). In this study, the optimal cut-off to predict ST was a
PRU value ≥222 (AUC 0.69, Po0.0001 in a receiver operating
characteristic analysis) [48]. In another prospective observa-
tional study enrolling 804 patients, clopidogrel resistance
(deﬁned as platelet aggregation by 10 μmol/L ADP ≥90th
percentile of controls (70%) at LTA) was associated with
increased risk of ST (8.6% vs. 2.3%, Po0.001) and was identi-
ﬁed as an independent predictor of ST (HR 3.08: 95% CI; 1.37–
7.16, P¼0.009) [49]. In a series of 1608 DES treated patients,
the 30-day incidence of deﬁnite ST and cumulative incidence
of death and ST were higher in clopidogrel low responders
(deﬁned by MEA cut off value of 416 AUmin) than in normal
responders (respectively 2.2% vs. 0.2%, Po0.0001; 3.1% vs.
0.6%, Po0.001) [50]. More recently, in the POPULAR (Point-of-
Care Platelet Function Assays Predict Clinical Outcomes in
Clopidogrel Pre-Treated Patients Undergoing Elective PCI)
study, which evaluated in an head-to-head comparison six
different platelet function test (LTA, VerifyNow, Platelet-
works, IMPACT-R, PFA ADP, PFA Innovance P2Y12), three
tests (LTA, VerifyNow and Plateletworks) were found to be
predictive of atherothrombotic events; however none of the
tests were identiﬁed to be predictive of ST [36]. Finally
another important issue is related to the increased risk of
ST associated to the presence of dual non-responsiveness to
both clopidogrel and aspirin. An observational study invol-
ving 746 DES treated patients showed an incidence of dual
non-responsiveness to clopidogrel and aspirin (evaluated by
LTA) of 6%; in this group, the incidence of deﬁnite/probable
ST (11.1%) was signiﬁcantly higher than in patients respon-
ders to both clopidogrel and aspirin, or in patients withisolate clopidogrel or aspirin hyporesponsiveness (respec-
tively 2.1%, Po0.001; 2.2%, Po0.005; and 2.3%, Po0.005) [51].4. Issues on tailored antiplatelet therapy
Once established HPR as a risk factor for development of ST,
the issue remains to ﬁnd a strategy to prevent this condition.
One possibility to achieve a greater platelet inhibition resides
in the administration of higher dose of clopidogrel. In the
GRAVITAS (Gauging Responsiveness with A VerifyNow assay-
Impact on Thrombosis And Safety) trial, 2214 patients with
HPR after coronary stenting were randomized to receive
clopidogrel high dose (600 mg loading dose plus 150mg daily
thereafter) vs. a standard dose (no additional loading dose
plus conventional 75 mg daily). Platelet reactivity, after PCI,
was assessed by VerifyNow P2Y12 assay (Accumetrics, Inc.,
San Diego, California). At 6-month follow-up no signiﬁcant
difference in the incidence of composite primary end point
(cardiovascular death, nonfatal MI, or ST) was observed
between patients who received clopidogrel high dose and
standard dose (2.3% vs. 2.3%, HR 1.01, 95% CI 0.58–1.76;
P¼0.97) [52]. These disappointing results suggested the scarce
effectiveness of tailoring antiplatelet treatment on the basis of
bedside platelet function test. However, different aspects of
GRAVITAS need to be discussed. One potential problem is the
timing of platelet reactivity assessment (12–24 h after PCI), as
during the ﬁrst 24 h after the procedure platelet reactivity
could increase in reason of PCI itself [53]. Another important
point is the low risk proﬁle of the population enrolled, which
was unlike to additionally beneﬁt from a more aggressive
antiplatelet treatment. Other trials have tested the assump-
tion to achieve a better outcome with a more aggressive use of
antiplatelet drug in patients on clopidogrel HPR (Table 1).
Aradi et al. in a small study found a signiﬁcant decrease in
platelet reactivity, assessed by LTA, with the administration
of 1 month of clopidogrel 150mg maintenance dose in HPR
patients. The primary composite end point (cardiovascular
death, MI or target vessel revascularization, TVR) was higher
in HPR patients receiving clopidogrel standard dose vs. HPR
patients receiving double clopidogrel dose (24.6% vs. 3.1%,
P¼0.01) or vs. patients with normal platelet reactivity (9.4%,
P¼0.01) [54]. In the EFFICIENT (EFFect of hIgh dose ClopIdogrel
treatmENT) trial in elective PCI patients with clopidogrel
resistance (deﬁned as a percent of inhibition lower than 40%
at VerifyNow P2Y12 Assay), the administration of higher
clopidogrel dose (150 mg) was more effective than the stan-
dard dose in preventing MACCE [55]. Bonello et al. showed
better clinical outcomes by using incremental clopidogrel
loads to overcome HPR as assessed by VASP [56,57]. The
advent of new more potent P2Y12 inhibitors has offered
new options to reduce the rate of patients with inadequate
inhibition of P2Y12 receptor [58,59]. The TRIGGER-PCI (Testing
platelet Reactivity In patients underGoing elective stent pla-
cement on clopidogrel to Guide alternative thErapy with
pRasugrel) trial investigated the effectiveness and the safety
of prasugrel vs. clopidogrel in patients with HPR after non-
urgent PCI with DES implantation [60]. This study demon-
strated the efﬁcacy of switching from clopidogrel to prasugrel
to achieve greater platelet inhibition; however, no clinical
Table 1 – Principal trials investigating the role of tailored antiplatelet strategy with P2Y12 inhibitors in percutaneous
coronary intervention.
Trials Design and study population Antiplatelet strategies Laboratory
methods and HPR
deﬁnition
Main results
GRAVITAS
[52]
2214 patients with high
platelet on-treatment platelet
reactivity 12–24 h after PCI
with drug eluting stent
Clopidogrel high dose (600 mg
load dose 150 mg daily
thereafter) or clopidogrel
standard dose (no additional
loading dose, 75 mg daily) for
6 months
VerifyNow Assay
PRU ≥230
No significant difference in
the incidence of
cardiovascular death,
nonfatal MI, or ST between
two groups
Aradi et al.
[54]
A total population of 200
patients screened for platelet
reactivity and scheduled for
elective PCI. Randomized 78
patients with high on
treatment platelet reactivity
12–24 h after 600 mg
clopidogrel loading dose
Clopidogrel high maintenance
dose (150 mg daily) or
clopidogrel standard
maintenance dose (75 mg
daily) for 4 weeks
ADP 5 μmol/L
induced maximal
aggregation values
≥34% (LTA)
CV death, MI or TVR was
significantly higher in the
HPRþ75 mg group compared
to patients with high
clopidogrel maintenance dose
or to patients with normal
platelet reactivity
EFFICIENT
[55]
A population of 192 screened
for platelet reactivity and
scheduled for elective PCI.
Randomized 94 patients with
high on treatment platelet
reactivity after 5 days of
treatment with ASA 100 mg
and Clopidogrel 75 mg
Clopidogrel high maintenance
dose (150 mg daily) or
clopidogrel standard
maintenance dose (75 mg
daily) for 4 weeks
VerifyNow Assay
percent of
inhibition o40%,
ARU≥550
6 months MACCE significantly
higher in the HPRþ75 mg
group compared to patients
randomized to 150 mg
clopidogrel or to patients with
HPR
Bonello
et al. [56]
162 randomized patients
undergoing PCI screened for
platelet reactivity 24 h after a
600 mg clopidogrel load
VASP guided group (three
additional 600 mg clopidogrel
loads in 24 h) or control group
(clopidogrel standard dose
without additional load)
VASP index 450% 1 month MACCE significantly
higher in clopidogrel control
group
Bonello
et al. [57]
429 randomized patients with
a low clopidogrel response
after a 600-mg LD undergoing
PCI (screened for platelet
reactivity within 24 h after
load)
VASP guided group (three
additional 600 mg clopidogrel
loads in 24 h) or control group
(clopidogrel standard dose
without additional load)
VASP index 450% Rate of stent thrombosis was
significantly lower in the
VASP-guided group
TRIGGER-
PCI [60]
423 randomized patients
screened for HPR between 2
and 7 h after clopidogrel
75 mg maintenance dose the
morning after PCI
Clopidogrel (75 mg daily) vs.
Prasugrel (10 mg daily)
VerifyNow Assay
PRU 4208
Prasugrel treatment was
effective in reducing HPR but
no clinical benefit for the low
rate of adverse ischemic
events
RESPOND
[61]
2-way crossover design
enrolling 98 patients
Phase 1: nonresponders
(n¼41) and responders (n¼57)
randomly received
clopidogrel (600 mg/75 mg
once daily) or ticagrelor
(180 mg/90 mg twice daily) for
14 days. Phase 2: all
nonresponders switched
treatment
ADP 20 μmol/L
induced the
absolute change in
platelet aggregation
(maximum extent)
was ≤10%
Treatment with ticagrelor,
regardless of clopidogrel
response, induces a reduction
of platelet reactivity below
the cut off point for ischemic
events
ARCTIC
[63]
2440 scheduled for elective
PCI
Monitoring group (adjustment
of antiplatelet therapy
according platelet function
test) or Conventional group
(conventional treatment not
adjusted according platelet
function test)
VerifyNow Assay
ARU ≥550 PRU ≥235
No difference in incidence of
death, MI, ST, stroke or urgent
revascularization at 1 year
follow up
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for HPR. Similarly the RESPOND (Response to Ticagrelor in
Clopidogrel Nonresponders and Responders and the Effect of
Switching Therapy) trial [61] has shown that treatment with
ticagrelor, regardless of clopidogrel response, induces a reduc-
tion of platelet reactivity below the cut off point for ischemicevents (deﬁned as 459% 20 μmol/L ADP-induced maximal
platelet aggregation, ≥235 PRU based on the VerifyNow
P2Y12 assay, and 450% Platelet Reactivity Index based on
the VASP phosphorylation assay). Recently a meta-analysis of
10 randomized trials testing the efﬁcacy of intensiﬁed anti-
platelet therapy on the basis of platelet reactivity shows the
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 1 5 1 – e 1 5 7 e155effectiveness of a tailored treatment in reducing cardiovascu-
lar mortality. Interestingly the net clinical beneﬁt of the
tailored therapy was found to be greater in patients at higher
risk for ST [62].
More recently, the ARCTIC (Assessment by a Double
Randomization of a Conventional Antiplatelet Strategy ver-
sus a Monitoring-guided Strategy for Drug-Eluting Stent
Implantation and of Treatment Interruption versus Continua-
tion One Year after Stenting) trial [63] showed no signiﬁcant
improvement in clinical outcome in patients with an adjust-
ment of treatment strategy guided by platelet reactivity
assessed with VerifyNow. 2440 scheduled for PCI were ran-
domly assigned to a treatment based on platelet reactivity or
a conventional therapy. Treatment strategies in HPR patient
were the following: intravenous aspirin in case of aspirin
resistance and administration of glycoprotein IIb/IIIa inhibi-
tors, and an additional loading dose of clopidogrel (at a dose
of ≥600 mg) or a loading dose of prasugrel (at a dose of 60 mg)
for clopidogrel resistance. Subsequently patients received
daily dose of clopidogrel 150 mg or prasugrel 10 mg. Other
adjustments of treatment were evaluated with platelet func-
tion tests at 14 and 30 days after the procedure. At 1 year
follow-up the incidence of primary end point (death from any
cause MI, ST, stroke or transient ischemic attack, or urgent
revascularization) was 31.1% in conventional group and 34.6%
in the monitoring group (P¼0.10); in the same way no
difference was found in incidence of ST between two groups
(0.7% vs. 1.0%, P¼0.51).5. Conclusions
ST is currently considered one of the most serious and life-
threatening events following PCI with stent implantation.
Possible strategies to reduce the incidence of these complica-
tions could reside in the improvement of stent and device
technology, and in the optimization of periprocedural and
maintenance drug treatment. Although high residual platelet
reactivity has been demonstrated to be a predictor of ST, no
evidence thus far exists on the effectiveness of tailoring
antiplatelet therapy on the basis of platelet function tests.
Although achieving a more intense platelet inhibition,
switching from standard to an intensiﬁed treatment regimen
has failed to show any beneﬁt in terms of clinical events. The
reasons for this lack of beneﬁt are not clear; however they
may be related to the selection of antiplatelet strategy or
patient population. The option of selecting patients on the
basis of genetic proﬁle is also open, although no relevant data
are available yet on treatment tailoring based on genetic
testing. Nevertheless, individualized pharmacological treat-
ment in PCI patients represents one major aim in order to
prevent ischemic and bleeding complication following percu-
taneous procedure.
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